B-cell receptor pathway modulators in NHL

por Blum, Kristie A.
Publicado no Hematology Am Soc Hematol Educ Program (2015)

Incidence and outcomes of lymphoid malignancies in adolescent and young adult (AYA) patients in the United States

por Blum, Kristie A., Keller, Frank G., Castellino, Sharon, Phan, Anh, Flowers, Christopher R.
Publicado no Br J Haematol (2018)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma

por Bond, David A., Dotson, Emily, Awan, Farrukh T., Baiocchi, Robert A., Blum, Kristie A., Maddocks, Kami
Publicado no Clin Lymphoma Myeloma Leuk (2019)

Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and...

por Johnston, Jeffrey S., Phelps, Mitch A., Blum, Kristie A, Blum, William, Grever, Michael R., Farley, Katherine L., Dalton, James T
Publicado em 2008

A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

por Cohen, Jonathon B., Maddocks, Kami J., Huang, Ying, Christian, Beth A., Jaglowski, Samantha M., Flowers, Christopher R., Blum, Kristie A.
Publicado no Leuk Lymphoma (2017)

Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose

por Bond, David A., Huang, Ying, Ruppert, Amy S., Walker, Alison R., Dotson, Emily K., Roddy, Julianna, Blum, Kristie A., Christian, Beth A.
Publicado no Leuk Lymphoma (2016)

Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

por Baiocchi, Robert A., Alinari, Lapo, Lustberg, Mark E., Lin, Thomas S., Porcu, Pierluigi, Li, Xiaobai, Johnston, Jeffrey S., Byrd, John C., Blum, Kristie A.
Publicado em 2010

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

por Morrison, Vicki A., Jung, Sin-Ho, Johnson, Jeffrey, LaCasce, Ann, Blum, Kristie A., Bartlett, Nancy L., Pitcher, Brandelyn N., Cheson, Bruce D.
Publicado no Leuk Lymphoma (2014)

Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility

por Guidot, Daniel M., Switchenko, Jeffrey M., Nastoupil, Loretta J., Koff, Jean L., Blum, Kristie A., Maly, Joseph, Flowers, Christopher R., Cohen, Jonathon B.
Publicado no Leuk Lymphoma (2017)

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

por Leonard, John P., Jung, Sin-Ho, Johnson, Jeffrey, Pitcher, Brandelyn N., Bartlett, Nancy L., Blum, Kristie A., Czuczman, Myron, Giguere, Jeffrey K., Cheson, Bruce D.
Publicado no J Clin Oncol (2015)

A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

por Ji, Jia, Mould, Diane R., Blum, Kristie A., Ruppert, Amy S., Poi, Ming, Zhao, Yuan, Johnson, Amy J., Byrd, John C., Grever, Michael R., Phelps, Mitch A.
Publicado em 2013

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease

por Woyach, Jennifer A., Heerema, Nyla A., Zhao, John, McFaddin, Andrew, Stark, Amy, Lin, Thomas S., Andritsos, Leslie A., Blum, Kristie A., Flynn, Joseph M., Jones, Jeffrey A., Byrd, John C.
Publicado em 2009

Outcome of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Genetic Features

por Woyach, Jennifer A., Lozanski, Gerard, Ruppert, Amy S., Lozanski, Arletta, Blum, Kristie A., Jones, Jeffrey Alan, Flynn, Joseph M., Johnson, Amy J., Grever, Michael R., Heerema, Nyla A., Byrd, John C.
Publicado em 2012

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

por BLUM, KRISTIE A., HAMADANI, MEHDI, PHILLIPS, GARY S., LOZANSKI, GERARD, JOHNSON, AMY J., LUCAS, DAVID M., SMITH, LISA L., BAIOCCHI, ROBERT, LIN, THOMAS S., PORCU, PIERLUIGI, DEVINE, STEVEN M., BYRD, JOHN C.
Publicado em 2009

Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma

por Liu, Qing, Farley, Katherine L., Johnson, Amy J., Muthusamy, Natarajan, Hofmeister, Craig C., Blum, Kristie A., Schaaf, Larry J., Grever, Michael R., Byrd, John C., Dalton, James T., Phelps, Mitch A.
Publicado em 2008

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 100...

por Rizzieri, David A., Johnson, Jeffrey L., Byrd, John C., Lozanski, Gerard, Blum, Kristie A., Powell, Bayard L., Shea, Thomas C., Nattam, Sreenivasa, Hoke, Eva, Cheson, Bruce D., Larson, Richard A.
Publicado em 2014

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

por Lansigan, Frederick, Barak, Ian, Pitcher, Brandelyn, Jung, Sin‐Ho, Cheson, Bruce D., Czuczman, Myron, Martin, Peter, Hsi, Eric, Schöder, Heiko, Smith, Scott, Bartlett, Nancy L., Leonard, John P., Blum, Kristie A.
Publicado no Cancer Med (2018)

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

por Herman, Sarah E. M., Lapalombella, Rosa, Gordon, Amber L., Ramanunni, Asha, Blum, Kristie A., Jones, Jeffrey, Zhang, Xiaoli, Lannutti, Brian J., Puri, Kamal D., Muthusamy, Natarajan, Byrd, John C., Johnson, Amy J.
Publicado em 2011

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

por Alinari, Lapo, White, Valerie L, Earl, Christian T, Ryan, Timothy P, Johnston, Jeffrey S, Dalton, James T, Ferketich, Amy K, Lai, Raymond, Lucas, David M, Porcu, Pierluigi, Blum, Kristie A, Byrd, John C, Baiocchi, Robert A
Publicado em 2009

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

por Herman, Sarah E. M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.
Publicado em 2011